The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients
Key facts
- Who runs it
- Tang Ziren
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 64 people, planned
- Started
- 1 Dec 2024
- Ended
- 31 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Target Temperature Management Treatment
- Record updated
- 11 April 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- age between 18 and 80 years
- Glasgow Coma Scale score of less than 8 upon admission
- patients resuscitated after out-of-hospital cardiac arrest; and (4) patient or their legal representative has signed the informed consent form
Who cannot take part
- uncorrected persistent cardiogenic shock, defined as a systolic blood pressure below 90 mmHg despite treatment with fluid resuscitation, vasopressors, and inotropic agents
- cardiac arrest caused by irreversible factors such as trauma or poisoning
- cardiac arrest due to terminal conditions like advanced cancer
- pre-existing cerebrovascular disease or CT-confirmed intracerebral hemorrhage upon admission
- bradycardia or sick sinus syndrome following the return of spontaneous circulation
- pre-existing coagulation disorders or severe bleeding tendencies
- pregnant or breastfeeding women, or women of childbearing age with elevated serum hCG levels
- pre-arrest Cerebral Performance Category (CPC) score between 3 and 5
- presence of treatment limitations (such as refusal by the patient or legal representative to undergo advanced life support, including mechanical ventilation, chest compressions, or targeted temperature management)
- determination by the principal investigator that the patient is unsuitable for the trial
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.
The 2 groups in the trial
- 24-hour treatmentSham treatment, for comparison
Treatment: Target Temperature Management Treatment
- 72-hour treatmentExisting treatment, for comparison
Treatment: Target Temperature Management Treatment
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients (ITTC Trial): A Single-Center, Prospective, Randomized Controlled Trial
- Record updated
- 11 April 2025